Low-Dose Opiate Therapy for Discomfort in Dementia (L-DOT)

PHASE4CompletedINTERVENTIONAL
Enrollment

11

Participants

Timeline

Start Date

October 31, 2007

Primary Completion Date

December 31, 2011

Study Completion Date

June 30, 2014

Conditions
Alzheimer DiseaseDementiaDementia, VascularPain
Interventions
DRUG

hydrocodone/APAP w placebo PRN

Hydrocodone/acetaminophen 2.5/167 mg per 5 ml liquid three times daily (TID). With liquid placebo available PRN.

DRUG

hydrocodone/APAP

Participants judged as responders during Phase A continue the same dose of study medication (hydrocodone/acetaminophen 2.5/167 mg per 5 ml liquid TID). Otherwise, moved to a higher dose (hydrocodone/acetaminophen 5/500mg TID or the most appropriate formulary alternative). Participant can also receive up to 2 PRN administrations at the same dose levels as listed above, but not to exceed 2.5g of acetaminophen.

DRUG

placebo with hydrocodone/APAP PRN

Liquid placebo PRN. Also available PRN is Hydrocodone/acetaminophen 2.5/167 mg per 5 ml liquid.

Trial Locations (3)

35404

Tuscaloosa VA Medical Center, Tuscaloosa

Tuscaloosa Veterans Affairs Medical Center, Tuscaloosa

VA Medical Center, Tuscaloosa, Tuscaloosa

All Listed Sponsors
lead

VA Office of Research and Development

FED

NCT00385684 - Low-Dose Opiate Therapy for Discomfort in Dementia (L-DOT) | Biotech Hunter | Biotech Hunter